BMS Forms Translation Partnership with Tsinghua University

Bristol-Myers Squibb formed a new collaboration with Beijing's Tsinghua University to develop drugs for novel targets associated with autoimmune disease and cancer. The University's Innovation Center for Immune Therapy will do the research on the projects while BMS will have an option to license the candidates. In 2012, BMS collaborated with Tsinghua to discover targets and map their 3-D structural biology (see story). Now, the two entities are moving into drug development. BMS says the new collaboration shows its continued support of novel drug development in China. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:

Original Article: BMS Forms Translation Partnership with Tsinghua University

More From BioPortfolio on "BMS Forms Translation Partnership with Tsinghua University"